

References

S-226

1. Hsu J, Artz A, Mayer SA, et al. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. *Biol Blood Marrow Transplant*. 2018; 24(2):359-365.
2. American College of Obstetrics and Gynecology committee opinion no. 771: umbilical cord banking. *Obstet Gynecol*. 2019; 133(3):e249e253.
3. Saudemont A, Madrigal J. Immunotherapy after hematopoietic stem cell transplantation using umbilical cord blood-derived products. *Cancer Immunology, Immunotherapy*. 2017; 66(2):215-221.
4. Fuchs EJ, O'Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. *Blood*. 2021;137(3):420-428.
5. Poonsombudlert K, Kewcharoen J, Prueksapraopong C, Limpruttidham N. Post-transplant cyclophosphamide based haplo-identical transplant versus umbilical cord blood transplant: A meta-analysis. *Jpn J Clin Oncol*. 2019;49(10):924-931.
6. Li D, Li X, Liao L, Li N. Unrelated cord blood transplantation versus haploidentical transplantation in adult and pediatric patients with hematological malignancies-A meta-analysis and systematic review. *Am J Blood Res*. 2020;10(1):1-10.
7. Wu R, Ma L. Haploidentical hematopoietic stem cell transplantation versus umbilical cord blood transplantation in hematologic malignancies: A systematic review and meta-analysis. *Cell Transplant*. 2020;29:963689720964771.
8. Park D, Choi YH, Kang SH, Koh HS, et. al. Bone marrow aspirate concentrate versus human umbilical cord blood-derived mesenchymal stem cells for combined cartilage regeneration procedure in patients undergoing high tibial osteotomy: A systematic review and meta-analysis. *Medicina*. 2023; 59(3):634.
9. Volt, F., Ruggeri, A., Scigliuolo, G. M., et. al. Umbilical cord blood transplantation after graft failure from a previous hematopoietic stem cell transplantation. *Transplantation and cell ther*, 2022; 28(1):46-e1.
10. Omisirge (omidubicel-only), suspension for infusion, for intravenous use. [package insert]. Gamida Cell Inc. Boston. MA. Revised 02/2024.
11. Horwitz ME, Stiff PJ, Cutler C, et.al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: Results of a phase 3 randomized study. *Blood*. 202;138(16):1429-1440.